徐戎，女，博士，教授，博士生导师。1999年同济医科大学临床医学本科毕业留校任教至今。2006年获药理学硕士学位，2010年获药理学博士学位，2011至2014年在美国康奈尔医学院附属卫理公会医院研究所进行博士后研究。研究方向为肿瘤药理学、纳米医学、临床药理学。近年围绕如何利用纳米技术有效治疗恶性肿瘤进行了系统研究，并取得了显著研究成果。主持国家自然科学基金、湖北省自然科学基金杰出青年基金项目、湖北省卫计委青年人才项目、武汉市科技项目、华中科技大学院系自主创新研究基金重点项目。在Nat Biotechnol、ACS Nano、Small、Nanoscale、J Exp Clin Cancer Res、Int J Nanomedicine等高水平SCI杂志上以通讯作者或第一作者发表论文多篇。兼任中国药理学会临床药理专委会常务委员、肿瘤药理专委会常务委员、中国抗癌协会抗癌药物专委会常务委员、湖北省药理学会常务理事、湖北省医学会医学伦理学分会副主任委员、华中科技大学药物临床试验伦理委员会办公室主任。参编人卫版《临床药理学》规划教材（中、英文版）、《新编临床药物治疗学》研究生规划教材，《医学机能学实验教程》、《医学实验室安全与操作规范》。

一、主持的科研课题：

国家自然科学基金面上及青年基金项目

湖北省自然科学基金杰青项目

湖北省卫生和计划生育委员会青年人才项目

武汉市科技计划项目

华中科技大学院系自主创新研究基金重点项目

二、主要学术论文：

1.Wu Z, Zhu L, Mai J, Shen H,Xu R. Rad51 Silencing with siRNA delivered by porous silicon-based microparticle enhances the anti-cancer effect of doxorubicin in triple-negative breast cancer. J Biomed Nanotechnol. 2021 Dec1;17(12):2351-2363.

2.He W, Qin M, Cai Y, Gao X, Cao S, Wang Z, Chen H*,Xu R*. Downregulation of HOXC6 by miR-27a ameliorates gefitinib resistance in non-small cell lung cancer.Am J Cancer Res. 2021 Sep 15;11(9):4329-4346.

3.Ming JX, Wang ZC, Huang Y, Ohishi H, Wu RJ, Shao Y, Wang H, Qin MY, Wu ZL, Li YY, Chang Zhou S, Chen H, Liu H,Xu R. Fucoxanthin extracted from Laminaria Japonica inhibits metastasis and enhances the sensitivity of lung cancer to Gefitinib. J Ethnopharmacol. 2021 Jan 30;265:113302.

4.Wu ZL, Zhao J,Xu R. Recent advances in oral nano-antibiotics for bacterialinfection therapy.Int J Nanomedicine. 2020 Dec 1;15:9587-9610.

5.Gao X, Cai Y, Wang Z, He W, Cao S,Xu R, Chen H. Estrogen receptors promote NSCLC progression by modulating the membrane receptor signaling network: a systems biology perspective. J Transl Med. 2019 Sep 11;17(1):308.

6.Cao S, Wang Z, Gao X, He W, Cai Y, Chen H*,Xu R*. FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC. J Exp Clin Cancer Res. 2018 Sep 6;37(1):220.

7.Tang Y^#, Li Y^#,Xu R^#, Li S, Hu H, Xiao C, Wu H, Zhu L, Ming J, Chu Z, Xu H, Yang X, Li Z. Self-assembly of folic acid dextran conjugates for cancer chemotherapy. Nanoscale. 2018 Sep 20;10(36):17265-17274.

8.Mai J, Li X, Zhang G, Huang Y,Xu R, Shen Q, Lokesh GL, Thiviyanathan V, Chen L, Liu H, Zu Y, Ma X, Volk DE, Gorenstein DG, Ferrari M, Shen H. DNA thioaptamer with homing specificity to lymphoma bone marrow involvement.Mol Pharm. 2018 May 7;15(5):1814-1825.

9.Liu H, Mai J, Shen J, Wolfram J, Li Z, Zhang G,Xu R, Li Y, Mu C, Zu Y, Li X, Lokesh GL, Thiviyanathan V, Volk DE, Gorenstein DG, Ferrari M, Hu Z, Shen H. A novel DNA aptamer for dual targeting of polymorphonuclear myeloid-derived suppressor cells and tumor cells.Theranostics. 2018 Jan 1;8(1):31-44.

10.Mei C, Zhou S, Zhu L, Ming J, Zeng F,Xu R. Antitumor effects of laminaria extract fucoxanthin on lung cancer. Mar Drugs. 2017 Feb 15;15(2). pii: E39.

11.Wang Z, Kerketta R, Chuang YL, Dogra P, Butner JD, Brocato TA, Day A,Xu R, Shen H, Simbawa E, Al-Fhaid AS, Mahmoud SR, Curley SA, Ferrari M, Koay EJ, Cristini V. Theory and experimental validation of a spatio-temporal model of chemotherapy transport to enhance tumor cell kill. PLoS Comput Biol. 2016 Jun 10;12(6):e1004969.

12.Xu R^#, Zhang G^#, Mai J^#, Deng X^#, Segura-Ibarra V, Wu S, Shen J, Liu H, Hu Z, Chen L, Huang Y, Koay E, Huang Y, Liu J, Ensor JE, Blanco E, Liu X, Ferrari M, Shen H. An injectable nanoparticle generator enhances delivery of cancer therapeutics. Nat Biotechnol. 2016 Apr;34(4):414-8.

13.Zhu Y, He W, Gao X, Li B, Mei C,Xu R, Chen H. Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells. Sci Rep. 2015 Dec 4;5:17730.

14.Xia X, Mai J,Xu R, Perez JE, Guevara ML, Shen Q, Mu C, Tung HY, Corry DB, Evans SE, Liu X, Ferrari M, Zhang Z, Li XC, Wang RF, Shen H. Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response. Cell Rep. 2015 May 12;11(6):957-66.

15.Gizzatov A, Stigliano C, Ananta JS, Sethi R,Xu R, Guven A, Ramirez M, Shen H, Sood A, Ferrari M, Wilson LJ, Liu X, Decuzzi P. Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer. Cancer Lett. 2014 Sep 28;352(1):97-101.

16.Mai J, Huang Y, Mu C, Zhang G,Xu R, Guo X, Xia X, Volk DE, Lokesh GL, Thiviyanathan V, Gorenstein DG, Liu X, Ferrari M, Shen H. Bone marrow endothelium-targeted therapeutics for metastatic breast cancer. J Control Release. 2014 Aug 10;187:22-9.

17.Shen J^#,Xu R^#, Mai J^#, Kim HC, Guo X, Qin G, Yang Y, Wolfram J, Mu C, Xia X, Gu J, Liu X, Mao ZW, Ferrari M, Shen H. High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano. 2013 Nov 26;7(11):9867-80.

18.Shen H, Rodriguez-Aguayo C,Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res. 2013 Apr 1;19(7):1806-15.

19.Zhang M,Xu R, Xia X, Yang Y, Gu J, Qin G, Liu X, Ferrari M, Shen H. Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells. Biomaterials. 2014 Jan;35(1):423-31.

20.Xu R, Huang Y, Mai J, Zhang G, Guo X, Xia X, Koay EJ, Qin G, Erm DR, Li Q, Liu X, Ferrari M, Shen H. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small. 2013 May 27;9(9-10):1799-808.

三、获奖情况：

华中科技大学高水平科技论文奖

华中科技大学十佳优秀青年教工

华中科技大学十大科技新星

华中科技大学教学质量优秀二等奖

华中科技大学青年教师教学竞赛二等奖

美国国立癌症研究院德州抗癌药物中心优秀博士后奖

四、发明专利:

聚乙二醇与肿瘤坏死因子α或其类似物的偶联物及其医药用途

肿瘤坏死因子β类似物、其偶联物及其医药用途

五、联系方式：

电话：027-83691785邮箱：rongxu@hust.edu.cn

武汉市航空路13号同济医学院基础医学院2号楼15楼药理学系

(Updated in June, 2022)